TY - JOUR
T1 - Aortic insufficiency associated with Impella that required surgical intervention upon implantation of the durable left ventricular assist device
AU - Oishi, Hideo
AU - Kondo, Toru
AU - Fujimoto, Kazuro
AU - Mutsuga, Masato
AU - Morimoto, Ryota
AU - Hirano, Ken ichi
AU - Sawamura, Akinori
AU - Kazama, Shingo
AU - Kimura, Yuki
AU - Shibata, Naoki
AU - Kato, Hiroo
AU - Arao, Yoshihito
AU - Kuwayama, Tasuku
AU - Yamaguchi, Shogo
AU - Hiraiwa, Hiroaki
AU - Okumura, Takahiro
AU - Usui, Akihiko
AU - Murohara, Toyoaki
N1 - Funding Information:
T. O. received lecture fees from Ono Yakuhin, Medtronics, and Otsuka, and received research grants from Ono Yakuhin, Bayer, Daiichi-Sankyo, and Amgen Astellas (not in connection with the submitted work). A. U. received research grants from TERUMO, Edwards Lifesciences, JAPAN LIFELINE, Mitsubishi Tanabe, Medtronic Japan, Senko medical instrument, St. Jude Medical, Pfizer, Daiichi-Sankyo, iCorNet, Trestech, and NIPRO. T. M. received lecture fees and unrestricted research grants from the Department of Cardiology at Nagoya University Graduate School of Medicine, Bayer, Daiichi-Sankyo, Dainippon Sumitomo, Kowa, MSD, Mitsubishi Tanabe, Boehringer Ingelheim, Novartis, Pfizer, Sanofi-Aventis, Takeda, Astellas, Otsuka, and Teijin.
Publisher Copyright:
© 2020, The Japanese Society for Artificial Organs.
PY - 2020/12
Y1 - 2020/12
N2 - The Impella is an axial-flow percutaneous ventricular assist device for cardiogenic shock. In this report, we describe two patients who developed aortic insufficiency (AI) associated with Impella and required surgical intervention upon implantation of the durable left ventricular assist device (LVAD). Both patients presented with cardiogenic shock and underwent insertion of Impella 5.0 as a bridge to decision. The cardiac function in these patients did not improve and obtaining approval for heart transplantation required time. They were managed with Impella for 91 and 98 days, respectively. In both cases, moderate AI that was not present before Impella insertion was observed when the Impella was removed. Therefore, we performed aortic valve closure to control the AI during durable LVAD implantation. In patients with durable LVAD implantation, AI may occur and progress after the operation in several cases. Aortic valve surgery is often performed to prevent deterioration of AI, especially in patients with AI before the surgery. Hence, AI is an important complication following Impella device implantation as a bridge to decision. Careful observation of AI is essential when the Impella is removed as the evaluation of AI by echocardiogram during Impella management is cumbersome because of device-generated artifacts.
AB - The Impella is an axial-flow percutaneous ventricular assist device for cardiogenic shock. In this report, we describe two patients who developed aortic insufficiency (AI) associated with Impella and required surgical intervention upon implantation of the durable left ventricular assist device (LVAD). Both patients presented with cardiogenic shock and underwent insertion of Impella 5.0 as a bridge to decision. The cardiac function in these patients did not improve and obtaining approval for heart transplantation required time. They were managed with Impella for 91 and 98 days, respectively. In both cases, moderate AI that was not present before Impella insertion was observed when the Impella was removed. Therefore, we performed aortic valve closure to control the AI during durable LVAD implantation. In patients with durable LVAD implantation, AI may occur and progress after the operation in several cases. Aortic valve surgery is often performed to prevent deterioration of AI, especially in patients with AI before the surgery. Hence, AI is an important complication following Impella device implantation as a bridge to decision. Careful observation of AI is essential when the Impella is removed as the evaluation of AI by echocardiogram during Impella management is cumbersome because of device-generated artifacts.
UR - http://www.scopus.com/inward/record.url?scp=85086663866&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85086663866&partnerID=8YFLogxK
U2 - 10.1007/s10047-020-01184-x
DO - 10.1007/s10047-020-01184-x
M3 - Article
C2 - 32562105
AN - SCOPUS:85086663866
VL - 23
SP - 378
EP - 382
JO - Journal of Artificial Organs
JF - Journal of Artificial Organs
SN - 1434-7229
IS - 4
ER -